Background
Methods
Inclusion
Exclusion criteria
Statistical analysis
Results
Histology |
P
| ||||
---|---|---|---|---|---|
Infiltrating Ductal Carcinoma | Squamous Cell Carcinoma | ||||
N | %a | N | %a | ||
Race | |||||
White | 2259 | 83.33 | 540 | 79.65 | < 0.01 |
African American | 343 | 12.65 | 119 | 17.55 | |
Others | 109 | 4.02 | 19 | 2.80 | |
Unknown | 33 | 8 | |||
Charlson-Deyo Score | |||||
0 | 2346 | 85.50 | 555 | 80.90 | 0.02 |
1 | 328 | 11.95 | 104 | 15.16 | |
2 | 54 | 1.97 | 20 | 2.92 | |
3 | 16 | 0.58 | 7 | 1.02 | |
Grade | |||||
I | 476 | 18.90 | 62 | 11.33 | < 0.01 |
II | 1058 | 42.00 | 151 | 27.61 | |
III | 985 | 39.10 | 334 | 61.06 | |
Unknown/IV | 225 | 139 | |||
Lymphovascular Invasion | |||||
Absence | 768 | 79.67 | 185 | 85.65 | 0.04 |
Present | 196 | 20.33 | 31 | 14.35 | |
Not Applicable | 1780 | 470 | |||
T-Stage | |||||
T0-T1 | 1441 | 52.51 | 145 | 21.14 | < 0.01 |
T2 | 502 | 18.29 | 178 | 25.95 | |
T3 | 67 | 2.44 | 100 | 14.58 | |
T4 | 45 | 1.64 | 58 | 8.45 | |
Tx | 689 | 25.11 | 205 | 29.88 | |
N-Stage | |||||
N0 | 1373 | 50.04 | 331 | 48.25 | 0.228 |
N1 | 381 | 13.88 | 85 | 12.39 | |
N2 | 115 | 4.19 | 22 | 3.21 | |
N3 | 56 | 2.04 | 16 | 2.33 | |
Nx | 819 | 29.85 | 232 | 33.82 | |
M-Stage | |||||
M0 | 2250 | 82.00 | 490 | 71.43 | < 0.01 |
M1 | 49 | 1.79 | 23 | 3.35 | |
Mx | 445 | 16.22 | 173 | 25.22 | |
Estrogen Receptor | |||||
Negative | 569 | 21.95 | 421 | 74.91 | < 0.01 |
Positive | 2023 | 78.05 | 141 | 25.09 | |
Unknown | 152 | 124 | |||
Progesterone Receptor | |||||
Negative | 843 | 32.69 | 491 | 87.84 | < 0.01 |
Positive | 1736 | 67.31 | 68 | 12.16 | |
Unknown | 165 | 127 | |||
HER2b | |||||
Negative | 829 | 78.2 | 207 | 87.7 | < 0.01 |
Borderline | 31 | 2.9 | 2 | 0.9 | |
Positive | 200 | 18.9 | 27 | 11.4 | |
Unknown | 156 | 68 | |||
Breast Surgery | |||||
No_Surgery | 167 | 6.10 | 90 | 13.16 | < 0.01 |
Breast-conserving surgery | 1561 | 56.99 | 246 | 35.96 | |
Mastectomy | 1010 | 36.87 | 348 | 50.88 | |
Surgery (Types_Unknown) | 1 | 0.04 | 0 | 0.00 | |
Unknown | 5 | 2 | |||
Radiation Therapy | |||||
No | 1119 | 41.23 | 373 | 54.93 | < 0.01 |
Yes | 1595 | 58.77 | 306 | 45.07 | |
Unknown | 30 | 7 | |||
Chemotherapy | |||||
None | 1506 | 58.28 | 294 | 46.08 | < 0.01 |
Single-Agent Chemotherapy | 44 | 1.70 | 23 | 3.61 | |
Multiagent Chemotherapy | 1034 | 40.02 | 321 | 50.31 | |
Unknown | 160 | 48 | |||
Neoadjuvant chemotherapy | |||||
No | 1884 | 89.89 | 447 | 83.86 | < 0.01 |
Yes | 212 | 10.11 | 86 | 16.14 | |
Unknown | 91 | 14 | |||
Endocrine Therapy | |||||
No | 1110 | 42.53 | 567 | 85.91 | < 0.01 |
Yes | 1500 | 57.47 | 93 | 14.09 | |
Unknown | 134 | 26 |
Different treatment patterns between SCC and IDC patients
Response to neoadjuvant chemotherapy
Category 1 | |||||||||
Histology | CR | PR, CR/PR | No response | Total | P* | ||||
N | % | N | % | N | % | N | % | ||
IDC | 35 | 35.35 | 59 | 59.6 | 5 | 5.05 | 99 | 100 | 0.042 |
SCC | 8 | 26.67 | 16 | 53.33 | 6 | 20 | 30 | 100 | |
Category 2 | |||||||||
Histology | Response (CR, PR, CR/PR) | No response | Total | P* | |||||
N | % | N | % | N | % | ||||
IDC | 94 | 94.95 | 5 | 5.05 | 99 | 100 | 0.019 | ||
SCC | 24 | 80 | 6 | 20 | 30 | 100 |
Survival analysis
Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR(95%CI) |
P
| HR(95%CI) |
P
| |
Age | ||||
< =50 | 1 | 1 | ||
50–60 | 1.13 (0.89–1.44) | 0.301 | 1.10 (0.86–1.40) | 0.445 |
> 60 | 2.25 (1.86–2.74) | < 0.001 | 2.11 (1.72–2.60) | < 0.001 |
Race | ||||
White | 1 | 1 | ||
African American | 1.51 (1.26–1.80) | < 0.001 | 1.05 (0.87–1.27) | 0.576 |
Others | 0.43 (0.24–0.77) | 0.004 | 0.48 (0.27–0.85) | 0.012 |
Unknown | 0.53 (0.24–1.19) | 0.126 | 0.49 (0.22–1.10) | 0.082 |
Comorbidity score | ||||
Score 0 | 1 | 1 | ||
Score 1 | 2.17 (1.85–2.54) | < 0.001 | 1.65 (1.40–1.95) | < 0.001 |
Grade | ||||
I | 1 | 1 | ||
II | 1.20 (0.94–1.54) | 0.149 | 0.98 (0.76–1.26) | 0.877 |
III | 2.05 (1.62–2.58) | < 0.001 | 1.35 (1.05–1.74) | 0.02 |
Unknown/IV | 1.86 (1.39–2.49) | < 0.001 | 1.05 (0.77–1.42) | 0.767 |
T-stage | ||||
T0-T1 | 1 | 1 | ||
T2 | 2.24 (1.86–2.69) | < 0.001 | 1.65 (1.35–2.03) | < 0.001 |
T3–4 | 5.63 (4.60–6.90) | < 0.001 | 2.75 (2.14–3.55) | < 0.001 |
Tx | 1.25 (1.04–1.51) | 0.017 | 0.62 (0.45–0.85) | 0.003 |
N-stage | ||||
N0 | 1 | 1 | ||
N1 | 1.82 (1.49–2.22) | < 0.001 | 1.77 (1.43–2.18) | < 0.001 |
N2–3 | 3.61 (2.90–4.49) | < 0.001 | 2.18 (1.69–2.83) | < 0.001 |
Nx | 1.12 (0.94–1.32) | 0.197 | 0.95 (0.70–1.30) | 0.764 |
M-stage | ||||
M0 | 1 | 1 | ||
M1 | 8.47 (6.42–11.17) | < 0.001 | 4.50 (3.29–6.16) | < 0.001 |
Mx | 2.04 (1.74–2.39) | < 0.001 | 1.90 (1.53–2.36) | < 0.001 |
Histology | ||||
Infiltrating Ductal Carcinoma | 1 | 1 | ||
Squamous Cell Carcinoma | 2.39 (2.06–2.77) | < 0.001 | 1.37 (1.15–1.64) | < 0.001 |
Lymphovascular invasiona | ||||
Absence | 1 | Not included | ||
Presence | 1.91 (1.37–2.67) | < 0.001 | ||
Not applicable/Unknown | 2.18 (1.63–2.91) | < 0.001 | ||
Estrogen Receptor | ||||
Negative | 1 | 1 | ||
Positive | 0.53 (0.46–0.61) | < 0.001 | 0.86 (0.67–1.10) | 0.218 |
Unknown | 0.85 (0.67–1.08) | 0.195 | 2.46 (0.60–10.15) | 0.212 |
Progesterone Receptor | ||||
Negative | 1 | 1 | ||
Positive | 0.56 (0.48–0.65) | < 0.001 | 0.96 (0.76–1.20) | 0.724 |
Unknown | 0.92 (0.73–1.16) | 0.484 | 0.31 (0.08–1.27) | 0.103 |
HER2a | ||||
Negative | 1 | Not included | ||
Positive | 0.83 (0.57–1.22) | 0.347 | ||
Borderline/Unknown | 1.20 (0.87–1.66) | 0.266 | ||
Surgery | ||||
Breast-conserving surgery | 1 | 1 | ||
Mastectomy | 2.22 (1.90–2.59) | < 0.001 | 1.26 (1.04–1.54) | 0.02 |
Others/Unknown | 7.05 (5.77–8.62) | < 0.001 | 6.57 (5.04–8.55) | < 0.001 |
Radiation therapy | ||||
No | 1 | 1 | ||
Yes | 0.54 (0.47–0.62) | < 0.001 | 0.92 (0.77–1.10) | 0.351 |
Unknown | 0.50 (0.24–1.05) | 0.067 | 0.54 (0.25–1.17) | 0.12 |
Chemotherapy | ||||
No | 1 | 1 | ||
Yes | 0.89 (0.77–1.03) | 0.116 | 0.67 (0.55–0.80) | < 0.001 |
Unknown | 0.72 (0.53–0.99) | 0.043 | 0.61 (0.43–0.85) | 0.004 |
Endocrine therapy | ||||
No | 1 | 1 | ||
Yes | 0.44 (0.38–0.51) | < 0.001 | 0.60 (0.50–0.73) | < 0.001 |
Unknown | 0.56 (0.40–0.78) | < 0.001 | 0.77 (0.54–1.09) | 0.145 |